Document Detail


Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.
MedLine Citation:
PMID:  22500149     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Heart failure is a frequent complication after acute myocardial infarction (MI) and carries a poor prognosis. Current treatments inhibit the renin-angiotensin-aldosterone system but suppression of aldosterone may be incomplete. The aldosterone antagonist spironolactone has been shown to improve survival in patients with chronic, severe heart failure. Eplerenone is a selective aldosterone antagonist expected to have a lower incidence of hormonal side effects than spironolactone.
AIMS: To assess the evidence on the therapeutic value of eplerenone for treatment of heart failure in adults.
EVIDENCE REVIEW: The evidence base consists of one large double-blind placebo-controlled multicenter randomized trial in over 6000 patients with postmyocardial infarction (MI) heart failure, comparing eplerenone plus standard therapy with placebo plus standard therapy. All the main outcomes were patient-oriented. Evidence from this trial shows that eplerenone improves survival and reduces cardiovascular hospitalization/mortality, compared with standard treatment alone. The incidence of hormonal side effects is no greater than with placebo. The risk of hyperkalemia is significantly increased, especially in patients with low creatinine clearance. Eplerenone was both more effective and more costly than standard treatment alone. The cost-effectiveness ratio has been estimated at $US10 402-21 876 per life-year gained.
PLACE IN THERAPY: Eplerenone reduces mortality compared with current treatment alone in patients with post-MI heart failure, at additional cost. Direct comparative evidence is needed to assess its efficacy versus spironolactone. It may be valuable in patients who are intolerant to the hormonal side effects of spironolactone.
Authors:
Carole Nadin
Related Documents :
22447889 - Effect of a multifaceted intervention on use of evidence-based therapies in patients wi...
22772599 - Long-term prognosis after primary pci in unselected patients with st-elevation myocardi...
22343639 - Topographic location of acute pontine infarction is associated with the development of ...
22917799 - Mentality and organisational changes are key to developing primary angioplasty.
21239339 - Percutaneous coronary angioscopy current status and future directions.
11177669 - Are all beta-blockers the same for chronic heart failure?
20651629 - Report of selective cortical infarcts in the primate clot model of vasospasm after suba...
2806299 - Relevance of subtle echocardiographic findings in the early diagnosis of the concealed ...
10525239 - Preventive effects of the heparin-coated stent on restenosis in the porcine model.
Publication Detail:
Type:  Journal Article     Date:  2005-06-30
Journal Detail:
Title:  Core evidence     Volume:  1     ISSN:  1555-1741     ISO Abbreviation:  Core Evid     Publication Date:  2005  
Date Detail:
Created Date:  2012-04-13     Completed Date:  2012-10-02     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101256593     Medline TA:  Core Evid     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  125-41     Citation Subset:  -    
Affiliation:
Core Medical Publishing, Knutsford, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topiramate: the evidence for its therapeutic value in the prevention of migraine.
Next Document:  Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hy...